JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Originally published In Press as doi:10.1074/jbc.M111122200 on December 18, 2001

J. Biol. Chem., Vol. 277, Issue 12, 10315-10322, March 22, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/12/10315    most recent
M111122200v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kishima, Y.
Right arrow Articles by Nakamura, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kishima, Y.
Right arrow Articles by Nakamura, H.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Hepatoma-derived Growth Factor Stimulates Cell Growth after Translocation to the Nucleus by Nuclear Localization Signals*

Yoshihiko KishimaDagger , Hiroyasu YamamotoDagger , Yoshitaka IzumotoDagger , Kenya YoshidaDagger , Hirayuki EnomotoDagger , Mitsunari YamamotoDagger , Toshifumi KurodaDagger , Hiroaki ItoDagger , Kazuyuki Yoshizaki§, and Hideji NakamuraDagger

From the Dagger  Department of Molecular Medicine, Osaka University Graduate School of Medicine, and the § Department of Medical Science I, School of Health and Sport Science, Osaka University, Yamada-oka 2-2, Suita, Osaka 565-0871, Japan

Received for publication, November 20, 2001

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Hepatoma-derived growth factor (HDGF) is the original member of the HDGF family of proteins, which contains a well-conserved N-terminal amino acid sequence (homologous to the amino terminus of HDGF; hath) and nuclear localization signals (NLSs) in gene-specific regions other than the hath region. In addition to a bipartite NLS in a gene-specific region, an NLS-like sequence is also found in the hath region. In cells expressing green fluorescence protein (GFP)-HDGF, green fluorescence was observed in the nucleus, whereas it was detected in the cytoplasm of cells expressing GFP-HDGF with both NLSs mutated or deleted. GFP-hath protein (GFP-HATH) was distributed mainly in the nucleus, although some was present in the cytoplasm, whereas GFP-HDGF with a deleted hath region (HDGFnonHATH) was found only in the nucleus. Exogenously supplied GFP-HDGF was internalized and translocated to the nucleus. GFP-HATH was internalized, whereas GFP-HDGFnonHATH was not. Overexpression of HDGF stimulated DNA synthesis and cellular proliferation, although HDGF with both NLSs deleted did not. Overexpression of HDGFnonHATH caused a significant stimulation of DNA synthesis, whereas that of hath protein did not. HDGF containing the NLS sequence of p53 instead of the bipartite NLS did not stimulate DNA synthesis, and truncated forms without the C- or N-terminal side of NLS2 did not. These findings suggest that the gene-specific region, at least the bipartite NLS sequence and the N- and C-terminal neighboring portions, is essential for the mitogenic activity of HDGF after nuclear translocation.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Hepatoma-derived growth factor (HDGF)1 is the first member of the HDGF family of proteins that contain a well-conserved N-terminal amino acid sequence which we call the hath (homologous to amino terminus of HDGF) region (1, 2). HDGF was purified from the conditioned medium of human hepatoma-derived HuH-7 cells, which proliferate autonomously in a serum-free chemically defined medium, and its complementary DNA was cloned from a HuH-7 cell cDNA library (1, 3). HDGF has growth-stimulating activity in fibroblasts, hepatoma cells, vascular smooth muscle cells, and endothelial cells (1, 3-5). Its deduced amino acid sequence demonstrated that it lacked a signal peptide-like hydrophobic sequence essential for classic secretion. However, the conditioned medium of COS7 cells transfected with cDNA expressing copious amounts of human HDGF showed growth-stimulating activity (1, 4). Furthermore, HDGF family proteins have a basic motif homologous to the reported consensus sequences for bipartite nuclear localization signals (NLSs) in gene-specific amino acid sequences other than the hath region of the molecule (1, 2, 6, 7). Additionally, an NLS-like basic amino acid-rich region is found in the hath region. Indeed, one of the HDGF family proteins, HDGF-related protein (HRP)-1 is detected immunohistochemically in the nucleus of germ cells, and another member, HRP-3, can translocate to the nucleus of its target cells (6, 7). Recently, HDGF was detected in the nucleus using anti-C terminus HDGF antibody and found to co-localize with the proliferating cell nuclear antigen in vascular smooth muscle cells (5). Among the growth factors, cytokines, and hormones identified previously, the following polypeptide factors have been reported to contain one or more NLSs and to undergo nuclear translocation for mitogenesis: acidic or basic fibroblast growth factor (FGF), FGF-3, schwannoma-derived growth factor (SDGF), ciliary neurotrophic factor, amphiregulin, angiogenin, and lens epithelium-derived growth factor (LEDGF) (8-23). These findings prompted us to study whether HDGF translocates to the nucleus via these NLSs, and whether its nuclear translocation is essential for induction of cell growth activity.

In this study, we investigate the functional roles of the putative NLSs by use of PCR-directed mutagenesis and the relationship between its nuclear translocation ability and growth-stimulating activity in the HDGF molecule. Furthermore, we analyze which part of the HDGF molecule is essential for internalization and the mitogenic activity.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Plasmid Construction of Truncated and Mutant Forms of HDGF-- We have named an NLS-like basic amino acid-rich region in the hath region and the basic region homologous to a bipartite NLS in a gene-specific part as NLS1 and NLS2, respectively. We constructed chimera proteins of wild HDGF or 12 truncated or mutant forms. The truncated or mutant forms of HDGF were named as follows: hath region from Ser2 to Ser98 (HATH), HDGF with deleted hath region (HDGFnonHATH), truncated form consisting of peptide from Ser2 to Lys170 (HDGF-LA), truncated form consisting of peptide from Ser2 to Leu154 (HDGF-SA), truncated form consisting of peptide from Lys155 to C-terminal Leu240 (HDGF-LP), truncated form consisting of peptide from Glu171 to C-terminal Leu240 (HDGF-SP), NLS1-mutated HDGF (HDGFmN1), NLS2-mutated HDGF (HDGFmN2), both NLS1- and NLS2-mutated HDGF (HDGFmN1mN2), both NLS1- and NLS2-deleted HDGF (HDGFdN1dN2), hath region with mutated NLS1 (HATHmN1), and hath region with deleted NLS1 (HATHdN1) (see Fig. 1 below).

First, we constructed four mutants of two putative NLSs in the HDGF molecule. The four HDGF mutants were HDGFmN1, HDGFmN2, HDGF with deleted NLS1 (HDGFdN1), and HDGF with deleted NLS2 (HDGFdN2). Deletions and mutations were introduced into the putative NLSs of human HDGF by PCR-directed mutagenesis. PCR was performed using appropriate synthetic oligonucleotides as primers and full-length HDGF cDNA as template. The point mutations introduced into NLS1 were Lys75 (AAG) to Asn (AAC), Lys78 (AAG) to Asn (AAT), Arg79 (AGG) to Gln (CAG), and Lys80 (AAA) to Asn (AAT). A BstEII site was created by changing the codon of Gly74 from GGC to GGT and used to make a PCR-generated fragment spanning the mutated NLS1. The same strategy was used in the construction of NLS2 point mutations. The amino acid changes were Lys155 (AAG) to Asn (AAT), Arg156 (AGG) to Gln (CAG), Arg157 (AGA) to Gln (CAA), Lys167 (AAA) to Asn (AAT), and Lys170 (AAG) to Asn (AAT). A XbaI site was introduced by changing the codons of Leu161 from TTG to CTT and Leu162 from CTG to CTA. The junction point of the in-frame deletion mutants of NLS1 was made using an NruI linker, which made a change of Gly79 (GGG) to Ala (GCC). Deletion mutants of NLS1 also include an XhoI restriction site at the junction point with no amino acid substitution. Briefly, for HDGFdN1, two PCR products were amplified using HF-S1 and dN1-S, described below as sense primers, and dN1-R and HF-R1 as antisense primers, which contained only sequences upstream of NLS1 and downstream of NLS1, were ligated at the NarI site. For HDGFmN1, two PCR products were amplified using HF-S1 and mN1-S, described below as sense primers, and mN1-R and HF-R1 as antisense primers, which contained NLS1 with mutations K75N, K78N, R79Q, and K80N, were ligated at the BstEII site. These HDGF cDNAs were inserted into the SpeI and XbaI sites of pBluescript II vectors. The cDNA for HDGFdN2 was constructed by ligation at the XhoI site after amplification by PCR using HF-S2 and dN2-S as sense primers, and dN2-R and HF-R2 as antisense primers. For HDGFmN2, two PCR products were amplified using HF-S2 and mN2-S as sense primers and mN2-R and HF-R2 as antisense primers, which contained an upstream sequence of NLS2 with mutations K155N, R156Q, and R157Q, and the downstream sequence of NLS2, with mutations K167N and K170N, was ligated at the XbaI site. The cDNA for HDGFdN1dN2 and HDGFmN1mN2 was constructed after amplification by PCR using HDGFdN1 and HDGFmN1 cDNA as templates, respectively, as described above for HDGFdN2 and HDGFmN2. These cDNAs were inserted into the HindIII and SpeI sites of the pRc/RSV vector. The sequences of primers were as follows: HF-S1, 5'-GCACTAGTCGATCCAACCGGCAGAAGGA-3'; dN1-R, 5'-AATGGCGCCAAACTTCTCCTTGGATT-3'; dN1-S, 5'-AATGGCGCCTTCAGCGAGGGGCTGTGGGA-3'; HF-R1, 5'-GCTCTAGACAGGCTCTCATGATCTCTGA-3'; mN1-R, 5'-GGGCTTGCCAAACTTCTCCTTGGATTC-3'; mN1-S, 5'-TTTGGTAACCCCAACAATCAGAATGGGTTCAGCGAGGGGC-3'; HF-S2, 5'-GCAAGCTTAGCCCCGCCATGTCGCGATC-3'; dN2-R, 5'-CGCTCGAGCGCTCCTTTCTCGTTCTTCTCCTT-3'; dN2-S, 5'-CGCTCGAGGCAGAAAACCCTGAAGGAGAG-3'; HF-R2, 5'-GCACTAGTCAGGCTCTCATGATCTCTGA-3'; mN2-R, 5'-CCTCTAGAAAGTCCCCTGCTTGCTGATTCAACGCTCCTTT-3'; and mN2-S, 5'-GCTCTAGAGGACTCTCCTAATCGTCCCAATGAGGC-3'.

For construction of green fluorescence protein (GFP)-chimera proteins, we amplified the wild HDGF and its six truncated forms by PCR using appropriate synthetic oligonucleotides as primers and full-length HDGF cDNA as template (Fig. 1). Furthermore, six mutant forms of HDGF were amplified by PCR using appropriate synthetic oligonucleotides as primers and the corresponding HDGF mutant cDNA as template. Primer 1, 5'-GCCCCAGATCTTCGCGATCCAACCGGCAGAAGGAG-3'; primer 2, 5'-AACATGTCGACCAGGCTCTCATGATCTCTGATGCC-3'; primer 3, 5'-AGTCAGTCGACGGAAGCCTTGACAGTAGGGTTGTTC-3'; primer 4, 5'-ACGTTGTCGACCTACTTGGGACGTTTAGGAGAGTCCTC-3'; primer 5, 5'-CCTGCGTCGACCTACAACGCTCCTTTCTCGTTCTTCTC-3'; primer 6, 5'-AAGGAAGATCTAAGAGGAGAGCAGGGGACTTGCTG-3'; primer 7, 5'-AACGTAGATCTGAGGCAGAAAACCCTGAAGGAGAG-3'; primer 8, 5'-TCAAGAGATCTGGCTATCAGTCCTCCCAGAAAAAGA-3'; primer 9, 5'-ACGAGAGATCTAAGGAGAAGTTTGGC-3'; and primer 10, 5'-CACAGGTCGACTCAGAACCCTTTCCTCTT-3'. For GFP-wHDGF and its mutant forms, including GFP-HDGFmN1, GFP-HDGFmN2, GFP-HDGFmN1mN2, and GFP-HDGFdN1dN2, primer 1 was used as the sense primer and primer 2 as the antisense primer. For GFP-HATH, GFP-HATHmN1, and GFP-HATHdN1, primers 1 and 3 were used as the sense and antisense primers, respectively. For GFP-HDGFnonHATH, primers 8 and 2 were used. For GFP-HDGF-LA and GFP-HDGF-SA, primer 1 was used as the sense primer and primers 4 and 5 were used as the antisense primers. For GFP-HDGF-LP and GFP-HDGF-SP, primer 2 was used as the antisense primer and primers 6 and 7 were used as the sense primers. For GFP-NLS1 (GFP fusion peptide consisting of 13 amino acids (Lys70 through Phe82) including NLS1), primers 9 and 10 were used as the sense and antisense primers, respectively. For GFP-NLS2 (GFP-NLS2 peptide (Lys155 through Lys170)), primers 4 and 6 were used as the antisense and sense primers, respectively. These 15 amplified cDNAs were inserted into the BglII and SalI sites of pEGFP-C1 vector (CLONTECH).


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 1.   Plasmid construction of truncated and mutant forms of HDGF. The shaded boxes show the NLS1 or NLS2 with mutated amino acids, and the mark and  shows the deletions in NLSs, as described under "Materials and Methods."

We constructed a mutant form of HDGF containing the NLS sequence of p53 (Lys305 through Lys321) instead of NLS2 (GFP-HDGF-p53NLS). The cDNA for the NLS of p53 was amplified by PCR using appropriate synthetic oligonucleotides: 5'-ATACGCTCGAGAAGCGAGCACTGCCCAACA-3' as the sense primer and 5'-TACGTCTCGAGTTTCTTCTTTGGCTGGGGA-3' as the antisense primer, and 5'-CTCGAGAAGCGAGCACTGCCCAACAACACCAGCTCCTCTCCCCAGCCAAAGAAGAAACTCGAG-3' corresponding to the NLS sequence of p53 as a template (24). The amplified cDNA was inserted into the XhoI site of HDGFdN1dN2 cDNA in pEGFP-C1.

We constructed myc-tagged proteins of wild HDGF and HDGFdN1dN2 for stable transformants. We amplified these cDNAs by PCR using 5'-GAGCCGGATCCGCTCGCGATCCAACCGGCAGAAGG-3' as the sense primer and 5'-AACATTCTAGACTACAGGCTCTCATGATCTCTGATG-3' as the antisense primer and the cDNA of HDGF and HDGFdN1dN2 as templates for myc-wHDGF and myc-HDGFdN1dN2, respectively. These amplified cDNAs were inserted into the BamHI and XbaI sites of the pEF-BOS vector (25). All PCR products were analyzed by restriction mapping and dideoxynucleotide sequencing.

Gene Transfection-- A human renal epithelial cell line (293 cells), a human hepatoblastoma cell line (HepG2 cells), and NIH3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FCS and antibiotics. Using a Mammalian transfection kit (Stratagene), 293 cells were transiently transfected with 6 µg of pEGFP-C1 containing cDNA of wild type or mutant forms of HDGF. HepG2 cells and NIH3T3 cells were co-transfected with 18 µg of pEF-BOS containing myc-tagged proteins and 2 µg of pST vector with the neomycin-resistance gene. Transfected cells were cultured in DMEM with 10% FCS in 3% CO2 at 37 °C, and 24 h later the DMEM was replaced with fresh medium and cultured for 3 days in 5% CO2 at 37 °C. After cultivation with 0.9 mg/ml neomycin for about 1 month, stable transformants of HepG2 cells and NIH3T3 cells were selected and cloned.

Visualization of GFP-chimera Proteins-- Living 293 cells transfected with pEGFP-C1 were evaluated on days 1, 2, 3, or 4 using confocal microscopy equipped for GFP visualization (488-nm excitation and FITC filter set). The conditioned media of 293 cells expressing GFP-chimera proteins were concentrated about 20-fold with Centricon 10 (Amicon) and then supplied to parent 293 cells. GFP-HDGF was examined after being purified from the conditioned medium of 293 cells expressing GFP-HDGF by heparin-Sepharose column chromatography, too. Three days later, we evaluated the intracellular fluorescence of these cells by confocal microscopy equipped for GFP visualization.

DNA Synthesis and Cell Proliferation Assay-- For the DNA synthesis assay, HepG2 cells and NIH3T3 cells expressing myc-tagged proteins were plated onto 96-well plates at a density of 2 × 103 cells/well in DMEM supplemented with 10% FCS. Twenty-four hours later, HepG2 cells and NIH3T3 cells were given fresh medium supplemented with 1% and 5% FCS, respectively. 2 or 4 days later, these cells were harvested, and [3H]thymidine (Thd) incorporation into DNA was measured. 293 cells expressing GFP-chimera proteins were plated onto 96-well plates at a density of 1 × 103 cells/well in DMEM supplemented with10% FCS. Twenty-four hours later, these cells were given fresh medium supplemented with 1% FCS, and the cells were harvested 4 days later.

For cell proliferation assay, HepG2 cells expressing myc-tagged proteins were plated onto 96-well plates at a density of 3 × 103 cells/well in DMEM supplemented with 10% FCS. After 24 h, HepG2 cells were given fresh medium supplemented with 10% FCS. Cell numbers were measured 2 and 4 days later using MTS colorimetric assay (Promega, Madison).

Western Blot Analysis-- HepG2 cells and NIH3T3 cells expressing myc-tagged proteins were cultured in 6-well plates to semiconfluence. Then cells were collected in 1.5-ml tubes and washed twice with phosphate-buffered saline. They were resuspended with 50 µl of 2× sample buffer (containing 0.5 M Tris(hydroxymethyl)aminomethane hydrochloride (pH 6.8), 10% SDS, 20% glycerol, and 0.01% bromphenol blue) and boiled at 99.9 °C for 5 min. After SDS-PAGE, each sample was transferred to an Immobilon membrane (Millipore, Bedford, TX). To detect myc-tagged proteins, membranes were incubated with anti-c-Myc monoclonal antibody (Ab-1 monoclonal) (Calbiochem, Cambridge, UK) and visualized with horseradish peroxidase-linked anti-mouse IgG using the enhanced chemiluminescence (ECL) system (Amersham Biosciences, Inc., UK). For detection of HDGF, we used rabbit polyclonal anti-C terminus human HDGF IgG and visualized the samples with horseradish peroxidase-linked anti-rabbit IgG using the ECL system.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

HDGF Translocates to the Nucleus in Living Cells via Nuclear Localization Signals-- HDGF contains a basic motif, 155KRRAGLLEDSPKRPK170 (basic residues underlined) homologous to the consensus sequences of bipartite NLS (NLS2), in a gene-specific area other than the hath region that consists of two clusters of basic residues separated by 10-12 amino acids, including proline residues (26, 27). Additionally, another NLS-like basic amino acid-rich region, 75KPNKRK80 (basic residues underlined) (NLS1), was found in the hath region (29). To clarify whether HDGF can translocate to the nucleus and which NLS is the functional sequence in the HDGF molecule, 293 cells were transfected with an expression vector encoding a GFP-tagged human HDGF cDNA and mutant HDGF cDNAs. As shown in Fig. 2, transfected cells expressing GFP-wHDGF showed green fluorescence only in the nucleus; however, cells expressing GFP-HDGFdN1dN2 or GFP-HDGFmN1mN2 showed fluorescence in the cytoplasm, not in the nucleus. In the transfected cells expressing GFP-HDGFmN2 or the truncated form without NLS2 (GFP-HDGF-SA), green fluorescence was detected in the nucleus, with some amount also found in the cytoplasm. HDGFmN1 translocated to the nucleus, as did the truncated forms with NLS2 (HDGF-LP and HDGFnonHATH), and neither was found in the cytoplasm. Most of the hath proteins with an intact NLS1 were transported to the nucleus, but variable amounts of hath protein remained in the cytoplasm. HATHmN1 and HATHdN1 remained in the cytoplasm. On the other hand, only NLS2 peptide could translocate green fluorescence protein to the nucleus. Most of the GFP-NLS1 was transported to the nucleus, showing a similar pattern of fluorescence to hath protein. NLS1 also has nuclear translocational potential, but its activity is weaker than that of NLS2. The two NLSs can together undoubtedly translocate HDGF protein to the nucleus.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 2.   Two nuclear localization signals function in the HDGF molecule. 293 cells were transiently transfected with pEGFP-C1 containing cDNA of wild type, truncated, or mutant forms of HDGF. The living 293 cells transfected with pEGFP-C1 were evaluated on day 3 using confocal microscopy equipped for GFP visualization (488-nm excitation and FITC filter set). The photographs show 293 cells expressing: a, mock, transfected with pEGF-C1 vector; b, GFP-wHDGF; c, GFP-HATH; d, GFP-HDGFnonHATH; e, GFP-HDGFmN1; f, GFP-HDGFmN2; g, GFP-HDGFmN1mN2; h, GFP-HDGFdN1dN2; i, GFP-HDGF-LA; j, GFP-HDGF-SA; k, GFP-HDGF-LP; l, GFP-HDGF-SP; m, GFP-HATHmN1; n, GFP-HATHdN1; o, GFP-NLS1+; p, GFP-NLS2.

Exogenously Added GFP-HDGF Is Internalized and Accumulated in the Nucleus-- Exogenous HDGF stimulated the growth of fibroblasts and endothelial cells, vascular smooth muscle cells, and some hepatoma cells. We investigated whether exogenously added GFP-HDGF was transported to the nucleus. After the addition of the concentrated conditioned medium of GFP-wHDGF, GFP-HDGFdN1dN2, GFP-HATH, or GFP-HDGFnonHATH-expressing cells, 293 cells were observed 24, 48, 72, and 96 h later by fluorescence detection. The purified fraction of GFP-wHDGF protein from the conditioned medium of 293 cells expressing GFP-wHDGF was examined also (data not shown). In 293 cells given GFP-wHDGF extracellularly, green fluorescence in the nucleus was observed from 72 h (Fig. 3). Nuclear fluorescence was also observed at 72 h in NIH3T3 cells given GFP-wHDGF. Whereas, green fluorescence was observed only in the cytoplasm, not nucleus, in 293 cells given GFP-HDGFdN1dN2. Interestingly, in cells treated with GFP-HATH extracellularly, green fluorescence was observed in both the cytoplasm and nucleus, similar to GFP-HATH-expressing cells. Exogenously supplied wild HDGF, HDGFdN1dN2, and hath protein show similar patterns of intracellular localization to their overexpressing cells. On the other hand, green fluorescence was not observed in wild 293 cells given GFP-HDGFnonHATH and GFP-HDGF-LP extracellularly, suggesting that HDGF protein with a deleted hath region could not be internalized into the cells.


View larger version (124K):
[in this window]
[in a new window]
 
Fig. 3.   Exogenously added GFP-HDGF accumulates in the nucleus of target cells. The conditioned media of 293 cells expressing GFP-chimera proteins of HDGF, HDGFdN1dN2, and HATH were concentrated about 20-fold by Centricon10 and then added to parent 293 cells extracellularly. Three days later, we evaluated the intracellular fluorescence by microscopy equipped for GFP visualization. The photographs show the 293 cells supplied exogenously: a, GFP-wHDGF; b, GFP-HDGFdN1dN2; c, GFP-HATH; and d, GFP-HDGFnonHATH.

Nuclear Translocation of HDGF Is Essential for Its Growth-stimulating Activity-- We investigated the role of nuclear translocation in the cell growth activity of HDGF. Because the effect of HDGF on cell proliferation is more prominent in cells overexpressing HDGF, we investigated the cell growth activity of truncated or mutant forms of HDGF by use of overexpressing cells. HDGF stimulated the growth of some hepatoma cells. First, we constructed myc-tagged HDGF expressing vector, and produced stable transformants. HepG2 cells have a low level of intrinsic HDGF (Fig. 4a). Native HDGF is detected as a band of about 40 kDa on SDS-PAGE analysis, and a smaller form of 35 kDa is supposed to be a degraded product or post-translationally modified form. After selection with neomycin, we cloned stable transformants of HepG2 cells that expressed myc-wHDGF and myc-HDGFdN1dN2. The expression of these myc-tagged proteins was confirmed by Western blotting using anti-myc antibody (Fig. 4c). The faint band of about 40 kDa detected by anti-myc antibody in each lane is a nonspecific band, because it is also detected in parent and mock cells. As shown in Fig. 5a, myc-wHDGF-expressing HepG2 cells showed a significantly stimulated DNA synthesis that was about two times greater than the level in neomycin-resistance gene-transfected (neo)-cells in culture medium supplemented with 1% FCS. On the other hand, myc-HDGFdN1dN2-expressing HepG2 cells did not show significantly stimulated DNA synthesis greater than neo cells. We also produced stable myc-wHDGF- and myc-HDGFdN1dN2-expressing NIH3T3 cells (Fig. 4, b and d). myc-wHDGF-expressing NIH3T3 cells showed significant stimulation of DNA synthesis 2.5 to 3 times greater than that in neo cells in culture medium supplemented with 5% FCS (Fig. 5b). However, myc-HDGFdN1dN2-expressing NIH3T3 cells showed no stimulated DNA synthesis. Additionally, the number of myc-wHDGF-expressing HepG2 cells increased significantly from 1.5- to 2-fold that of the parent cells or neo cells after a 4-day culture in medium supplemented with 10% FCS (Fig. 6). However, the increase in the number of myc-HDGFdN1dN2-expressing HepG2 cells was significantly lower than that of myc-wHDGF-expressing cells. Thus, the nuclear translocation potential seems to be essential to the growth-stimulating activity of HDGF.


View larger version (46K):
[in this window]
[in a new window]
 
Fig. 4.   Overexpression of myc-tagged HDGF proteins in stable transformants. The protein levels of wild type and mutant forms of HDGF expressed in stable transformants were evaluated by Western blotting. Myc-tagged wild HDGF was highly expressed in HepG2 cells and NIH3T3 cells relative to intrinsic HDGF in their neomycin-selected and parent cells, using an anti-C terminus HDGF polyclonal antibody. Myc-tagged HDGF and its mutant forms in stable transformants of HepG2 cells (a, b) and NIH3T3 cells (c, d) were detected with an anti-C terminus HDGF polyclonal antibody at a dilution of 1000-fold (a, c) or anti-myc monoclonal antibody at a dilution of 10-fold (b, d). In a and b: lane 1, parent HepG2; lanes 2 and 3, mock clones 1 and 2; lanes 4 and 5, clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 6 and 7, clones 1 and 2 expressing myc-wHDGF. In c and d: lane 1, parent NIH3T3; lanes 2 and 3, mock clones 1 and 2; lanes 4 and 5, clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 6 and 7, clones 1 and 2 expressing myc-wHDGF. Each arrow shows a protein band corresponding to intrinsic HDGF (I), myc-tagged wild type, or mutant HDGF (M).


View larger version (37K):
[in this window]
[in a new window]
 
Fig. 5.   HepG2 and NIH3T3 cells overexpressing wild type HDGF stimulate DNA synthesis, but cells overexpressing mutant forms of HDGF without NLSs do not. HepG2 cells were cultured in DMEM supplemented with 1% FCS for 96 h and then harvested for DNA synthesis. NIH3T3 cells were cultured in DMEM supplemented with 5% FCS for 48 h and then harvested. In a: HepG2 cells. Lanes 1 and 2, mock clones 1 and 2; lanes 3 and 4, clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 5 and 6, clones 1 and 2 expressing myc-wHDGF. In b: NIH3T3 cells. Lanes 1 and 2, mock clones 1 and 2; lanes 3 and 4, clones 1 and 2 expressing myc-HDGFdN1dN2; lanes 5 and 6, clones 1 and 2 expressing myc-wHDGF. *, p < 0.05 versus mock clones and myc-HDGFdN1dN2-expressing cells.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 6.   HepG2 cells overexpressing wild type HDGF stimulate cell proliferation, but cells overexpressing mutant forms of HDGF without NLSs do not. HepG2 cells were cultured in DMEM supplemented with 10% FCS, and 2 and 4 days later cell numbers were determined by the MTS method. Open and closed squares, mock clones 1 and 2; open and closed triangles, clones 1 and 2 expressing myc-HDGFdN1dN2; open and closed circles, clones 1 and 2 expressing myc-wHDGF. *, p < 0.05 versus mock clones and myc-HDGFdN1dN2-expressing cells.

Next, we examined DNA synthesis in the bulk of cells expressing GFP-chimera proteins of HDGF after neomycin selection for about 1 week. The GFP-protein-expressing 293 cells were microscopically examined for green fluorescence. As shown in Fig. 7, GFP-wHDGF-expressing 293 cells showed significantly stimulated DNA synthesis, about 85% greater than that of 293 cells transfected with vector only. However, GFP-HDGFdN1dN2-expressing cells and GFP-HDGFmN1mN2-expressing cells showed significantly diminished [3H]Thd incorporation to a level almost equal to that of cells transfected with vector only. GFP-HDGFmN1-expressing cells showed significantly stimulated DNA synthesis, whereas GFP-HDGFmN2-expressing cells did not. GFP-HATH-expressing cells did not show significantly stimulated DNA synthesis, although most of the hath protein was translocated to the nucleus (Fig. 7a). Furthermore, we investigated which part, excluding the hath region, functioned for growth-stimulating activity, by use of cells expressing GFP-chimera proteins. Interestingly, GFP-HDGFnonHATH-expressing cells showed significantly stimulated DNA synthesis, about 120% greater than that in neo cells, the level of which was almost equal to that of GFP-wHDGF-expressing cells (Fig. 7). However, neither GFP-HDGF-LA-expressing cells nor GFP-HDGF-LP-expressing cells showed significantly stimulated DNA synthesis, although both protein forms were transported to the nucleus (Fig. 7b). Furthermore, GFP-HDGF-p53NLS, which was translocated to the nucleus, did not stimulate DNA synthesis (Fig. 8). These findings suggest that hath protein alone does not have growth-stimulating activity and gene-specific areas other than the hath region contribute to the mitogenic activity of HDGF after translocation to the nucleus.


View larger version (39K):
[in this window]
[in a new window]
 
Fig. 7.   Increased DNA synthesis in 293cells expressing GFP-wHDGF or GFP-HDGFnonHATH but not in cells expressing GFP-HDGF without NLSs or GFP-HATH. 293 cells expressing GFP-chimera proteins of wild type HDGF, its mutant, or truncated forms were cultured in DMEM supplemented with1% FCS and were harvested 4 days later. In a: lane 1, mock, transfected with pEGFP-C1 vector; lane 2, GFP-HDGFmN1mN2; lane 3, GFP-HDGFdN1dN2; lane 4, GFP-HDGFmN1; lane 5, GFP-HDGFmN2; lane 6, GFP-HATH; lane 7, GFP-HDGFnonHATH; lane 8, GFP-wHDGF. In b: lane 1, mock; lane 2, GFP-HATH; lane 3, GFP-HDGFnonHATH; lane 4, GFP-HDGF-SA; lane 5, GFP-HDGF-LA; lane 6, GFP-HDGF-LP. *, p < 0.05 versus mock, GFP-HDGFmN1mN2, GFP-HDGFdN1dN2, and GFP-HATH; **, p < 0.001 versus mock, GFP-HATH, GFP-HDGF-SA, GFP-HDGF-LA, and GFP-HDGF-LP.


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 8.   HDGF containing the NLS sequence of p53 instead of NLS2 cannot stimulate DNA synthesis. a, microscopy of 293 cells expressing GFP-HDGF-p53NLS. The living 293 cells transfected with pEGFP-C1 containing HDGF-p53NLS were evaluated on day 3 using confocal microscopy equipped for GFP visualization (488-nm excitation and FITC filter set). b, DNA synthesis in 293 cells. 293 cells expressing GFP-HDGF-p53NLS were cultured in DMEM supplemented with 1% FCS, and were harvested 4 days later. Lane 1, mock; lane 2, GFP-HDGF-p53NLS; lane 3, GFP-wHDGF. *, p < 0.005 versus mock, GFP-HDGF-p53NLS.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Exogenously supplied HDGF stimulates the growth of fibroblasts, endothelial cells, smooth muscle cells, and some hepatoma cells, and is considered to function in these cells as an autocrine or paracrine factor (1, 3-5). HDGF contains not only a basic amino acid-rich region (NLS1) in the hath region but also a putative bipartite NLS (NLS2) in a gene-specific area other than the hath region. These experiments using GFP- chimera proteins demonstrated that HDGF could be translocated into the nucleus via these two NLSs. NLS2 translocated the truncated forms as well as whole HDGF protein to the nucleus, in the presence or absence of NLS1. On the other hand, variable amounts of the hath proteins and NLS2-mutated HDGF proteins remained in the cytoplasm. Furthermore, the NLS2 peptide translocated GFP to the nucleus completely, and NLS1 peptide translocated most of the GFP to the nucleus, although some amount remained in the cytoplasm. Thus, NLS2 functions as a major NLS signal in the HDGF molecule, and NLS1 may have the same ability of NLS but functions more weakly as an assistant for nuclear translocation. A mutated form without basic amino acids in the NLS sequences (HDGFmN1mN2) as well as NLS-deleted forms (HDGFdN1dN2, HATHdN1) could not be translocated to the nucleus. Thus, basic residues in NLSs are essential for the nuclear translocational potential of NLSs, as reported previously (26-28).

HDGF was detected in the nucleus of endothelial cells and smooth muscle cells by immunohistochemistry using an anti-C terminus HDGF antibody (5). We previously reported the cytoplasmic localization of HDGF in HuH-7 cells, using an anti-N terminus antibody generated in rabbit (1). Oliver and Al-Awqati (4) also showed a cytoplasmic localization in rat metanephrogenic mesenchymal cells with no signal in the nucleus, using immunoaffinity-purified anti-peptide antibody (the peptide used as antigen had the amino acid sequence of the hath region). One possible explanation for the difference in these findings is that antibodies used in the previous reports were generated against the N terminus of HDGF or the peptide in the hath region, and the antibodies in this study were generated against the C terminus of HDGF. Some amount of hath protein was also detected in the cytoplasm in the present study. These antibodies reacted with the HDGF molecule and with hath protein cleaved from HDGF, which is probably abundant in the cytoplasm of any cell type. However, in these previous studies, nuclear staining was not found. Therefore, either a specific cell type or stage of the cell cycle might influence the fate of the intracellular localization of HDGF. Conversely, some amount of imported HDGF in the target cells might accumulate and remain in the cytoplasm in any cell type, or it might shuttle between the cytoplasm and the nucleus during cell differentiation or at different stages of the cell cycle. The high mobility group-1 protein was reported to be present in both the cytoplasm and nucleus, and most of it was found in the cytoplasm in confluent cells whereas it was found in the nucleus in dividing cells (29). HDGF was co-localized with proliferating cellular nuclear antigen in the nucleus of proliferating vascular smooth muscle cells (4). It is reported that another member of the HDGF family, named LEDGF, changed its intracellular localization from the nucleus to the cytoplasm with culture temperature (30). Thus, HDGF may shuttle between the cytoplasm and nucleus as do LEDGF and high mobility group-1, depending on the phase of the cell cycle, the state of differentiation or the environmental conditions.

In this study, we showed that the nuclear translocation of HDGF was essential for its mitogenic activity. Overexpression of the gene-specific region (HDGFnonHATH) did significantly stimulate DNA synthesis, almost equal to the effect of wild HDGF, whereas hath protein could not. HDGFmN1 with intact NLS2 stimulated the DNA synthesis, suggesting that NLS1 was not essential for the mitogenic activity. Furthermore, an HDGF mutant containing the NLS sequence of p53 instead of NLS2, which had nuclear translocation ability, did not stimulate DNA synthesis, and truncated forms without the C- or N-terminal side of NLS2 (HDGF-LA and HDGF-LP) did not. We consider that the mitogenic activity disappeared, because a conformational change occurred upon replacement of the p53 NLS sequence of the NLS2 locus, or that the amino acid sequence itself, including NLS2, may be necessary for the activity, in addition to the ability for nuclear translocation. These findings suggest that the whole sequence of the gene-specific region of HDGF, or at least NLS2 and the N- and C-terminal neighboring portions, is essential for the mitogenic activity.

Recently, it has become evident that some polypeptide factors, subsequent to receptor-ligand internalization, may translocate to the nucleus, and that nuclear translocation may be essential for mitogenic activity. Induction of mitogenesis by FGF is directly dependent on nuclear localization, whereby the deletion of its NLS abolishes the mitogenic activity with no effect on other functions (11-13, 31-34). Additionally, nuclear localization has been reported to be essential for the mitogenic activity of SDGF, ciliary neurotrophic factor, amphiregulin, and angiogenin (18-23). The mitogenic activity of HDGF is dependent on nuclear translocation. Thus, HDGF may belong to a group of these growth factors that require nuclear translocation to induce mitogenic activity, at least as one signal pathway. Basic FGF stimulated cell proliferation and angiogenesis after internalization and translocation to the nucleus in a receptor-mediated manner (35). Exogenous acidic FGF was associated with the nucleus in a receptor-dependent manner, and some cell surface FGF receptors translocated to a perinuclear location as a functional tyrosine kinase (36, 37), suggesting that both the tyrosine kinase signal from the activated FGF receptor and growth factor internalization were required for the induction of cell proliferation (38). On the other hand, another group asserted that receptor-mediated endocytosis of acidic FGF does not result in its translocation to the nucleus, because acidic FGF, microinjected into the cytoplasm of baby hamster kidney cells, enters the cell nucleus by free diffusion and becomes trapped upon binding to nuclear structures (39). Because the receptor of HDGF has not yet been identified, it is not clear whether nuclear translocation is essential for the receptor-mediated signal transduction as seen in basic FGF and SDGF. However, it is notable that green fluorescence was detected in the nucleus 72 h after the extracellular addition of GFP-HDGF, suggesting that exogenously supplied HDGF was truly internalized. Furthermore, GFP-HATH protein was internalized, but GFP-HDGF-LP or GFP-HDGFnonHATH was not. Although the time until visualization, 72 h, seems to be longer for DNA synthesis, we consider that the accumulation of sufficient amounts of GFP proteins must be necessary to detect the fluorescence. These findings suggest that exogenously supplied HDGF is internalized into the cytoplasm, probably after binding to the cell membrane (possible receptor) via the hath region, and then is transported to the nucleus via NLS in the HDGF molecule.

The growth-stimulating behavior of the stable transformants overexpressing the growth factor lacking a signal peptide may be explained by the prediction that HDGF is largely sequestered in a cellular compartment different from that of its receptor. Non-secreted acidic FGF, lacking the secretion signal, functions in cell motility and invasive potential compared with the secreted form of acidic FGF encoding cDNA coupled to a signal peptide sequence, indicating its ability for intracellular signaling in a so-called intracrine manner (40). Our current findings demonstrating that the HDGF-producing cells have growth-stimulating activity after nuclear translocation may support the functional intracrine signaling of HDGF. HRP-1 and HRP-3 were detected in the nucleus by immunohistochemistry and GFP-tagged fluorescence microscopy (6, 7). Another member of the HDGF family, HRP-2, had a higher molecular weight than other HDGF proteins and was a more basic protein containing many Lys and Arg amino acids in a gene-specific region, strongly suggesting that it might be a transcriptional regulatory protein (2). p52/p75 were cloned first as transcriptional coactivators; however, they contain the hath region in the N-terminal sequence and, therefore, must belong to the HDGF family (41). Interestingly, p75 (which we would like to call HRP-5) was reported to be a survival and growth factor for lens epithelial cells, fibroblasts, and keratinocytes (23). Synthetic peptides containing the NLS of acidic FGF were able to stimulate DNA synthesis in an FGF receptor-independent manner after delivery into living NIH3T3 cells by a cell-permeable peptide import technique, suggesting that exogenous FGF was internalized and directly involved in the nuclear transport (31). Furthermore, basic FGF stimulated gene transcription in a cell-free system, suggesting a direct function in nuclear events (16). FGF-2 activated ribosomal DNA transcription and showed a strong affinity for histone H1. FGF-2 regulated gene expression through modulation of chromatin structure in the nucleus (42). In our study, HDGFnonHATH-overexpressing cells showed increased DNA synthesis, suggesting that HDGFnonHATH was transported to the nucleus directly and stimulated DNA synthesis. It may be postulated that HDGF translocates to the nucleus directly and regulates gene expression. Therefore, HDGF may function in an intracrine fashion for cell proliferation as well as having autocrine or paracrine functions, or it might function as a transcriptional regulatory protein after direct translocation to the nucleus in any cell type.

HDGF has no signal peptide, but some amount of HDGF was detected in the conditioned medium of HuH-7 cells, HepG2 cells, and COS cells overexpressing HDGF (1). Some growth factors were reported to have no signal peptides, such as FGF-1, -2, -9, and -11 through -14 and interleukin-1 (43-46). It is reasonable to consider that the HDGF protein in the conditioned medium is released from lysed or dead cells, although we cannot exclude the possibility that HDGF is secreted via an internal hydrophobic sequence as an internal signal sequence (1) or by a non-classic secretory pathway. Most of the HDGF present extracellularly must be a consequence of cell lysis and would not be physiological. However, we consider these factors to have possible roles under pathogenic conditions. For example, when the tissue was damaged and cells were destroyed by mechanical stress or inflammation, growth factors such as HDGF in the cytoplasm and/or nucleus were released, and these could act on adjacent progenitor cells and stimulate cell proliferation to repair the tissue. In any cell type, these non-receptor-mediated signals may induce cell proliferation or survival after direct translocation to the nucleus. These pathways might work for some factors as a primitive signal pathway in biological functions for cell survival and repair.

In summary, HDGF translocates to the nucleus via nuclear localization signals, mainly NLS2, in a gene-specific region as the major potential NLS, and NLS1 in the hath region may be an assistant. The nuclear translocation is essential for the mitogenic activity of HDGF. Exogenously supplied GFP-HDGF is undoubtedly internalized and translocated to the nucleus, although its receptor has not yet been identified. HDGF is supposed to be internalized into the cytoplasm after binding to a possible membrane receptor in the hath region and then translocated to the nucleus via mainly NLS in a gene-specific part other than the hath region. The gene-specific region, or at least NLS2 and the N- and C-terminal neighboring portions, may contribute to mitogenic activity in the HDGF molecule. HDGF (and other members of the HDGF family) may function as nuclear/growth factors in an autocrine, paracrine, and/or intracrine manner.

    FOOTNOTES

* The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed. Tel.: 81-6-6879-3837; Fax: 81-6-6879-3839; E-mail: nakamura@imed3.med.osaka-u. ac.jp.

Published, JBC Papers in Press, December 18, 2001, DOI 10.1074/jbc.M111122200

    ABBREVIATIONS

The abbreviations used are: HDGF, hepatoma-derived growth factor; NLS, nuclear localization signal; HRP, HDGF-related protein; FGF, fibroblast growth factor; SDGF, schwannoma-derived growth factor; LEDGF, lens epithelium-derived growth factor; GFP, green fluorescence protein; DMEM, Dulbecco's modified Eagle's medium; FCS, fetal calf serum; FITC, fluorescein isothiocyanate; Thd, thymidine; MTS, 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

1. Nakamura, H., Izumoto, Y., Kambe, H., Kuroda, T., Mori, T., Kawamura, K., Yamamoto, H., and Kishimoto, T. (1994) J. Biol. Chem. 269, 25143-25149[Abstract/Free Full Text]
2. Izumoto, Y., Kuroda, T., Harada, H., Kishimoto, T., and Nakamura, H. (1997) Biochem. Biophys. Res. Commun. 238, 26-32[CrossRef][Medline] [Order article via Infotrieve]
3. Nakamura, H., Kambe, H., Egawa, T., Kimura, Y., Ito, H., Hayashi, E., Yamamoto, H., Sato, J., and Kishimoto, S. (1989) Clin. Chim. Acta 183, 273-284[CrossRef][Medline] [Order article via Infotrieve]
4. Oliver, J. A., and Al-Awqati, Q. (1998) J. Clin. Invest. 102, 1208-1219[Medline] [Order article via Infotrieve]
5. Everett, A. D., Lobe, D. R., Matsumura, M. E., Nakamura, H., and McNamara, C. A. (2000) J. Clin. Invest. 105, 567-575[Medline] [Order article via Infotrieve]
6. Kuroda, T., Tanaka, H., Nakamura, H., Nishimune, Y., and Kishimoto, T. (1999) Biochem. Biophys. Res. Commun. 262, 433-437[CrossRef][Medline] [Order article via Infotrieve]
7. Ikegame, K., Yamamoto, M., Kuroda, T., Kishima, Y., Enomoto, H., Yoshida, K., Suemura, M., Kishimoto, T., and Nakamura, H. (1999) Biochem. Biophys. Res. Commun. 266, 81-87[CrossRef][Medline] [Order article via Infotrieve]
8. Jans, D. A. (1994) FASEB J. 8, 841-847[Abstract]
9. Prochiantz, A., and Theodore, L. (1995) Bioessays 17, 39-44[CrossRef][Medline] [Order article via Infotrieve]
10. Jans, D. A., and Hassan, G. (1998) Bioessays 20, 400-411[CrossRef][Medline] [Order article via Infotrieve]
11. Imamura, T., Engleka, K., Zhan, X., Tokita, Y., Forough, R., Roeder, D., Jackson, A., Maier, J. A., Hla, T., and Maciag, T. (1990) Science 249, 1567-1570[Abstract/Free Full Text]
12. Imamura, T., Tokita, Y., and Mitsui, Y. (1992) J. Biol. Chem. 267, 5676-5679[Abstract/Free Full Text]
13. Wiedlocha, A., Falnes, P. O., Madshus, I. H., Sandvig, K., and Olsnes, S. (1994) Cell 76, 1039-1051[CrossRef][Medline] [Order article via Infotrieve]
14. Baldin, V., Roman, A. M., Bosc-Bierne, I., Amalric, F., and Bouche, G. (1990) EMBO J. 9, 1511-1517[Medline] [Order article via Infotrieve]
15. Amalric, F., Baldin, V., Bosc-Bierne, I., Couderc, B., Guyader, M., Patry, V., Prats, H., Roman, A. M., and Bouche, G. (1991) Ann. N. Y. Acad. Sci. 638, 127-138[Medline] [Order article via Infotrieve]
16. Nakanishi, Y., Kihara, K., Mizuno, K., Masamune, Y., Yoshitake, Y., and Nishikawa, K. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 5216-5220[Abstract/Free Full Text]
17. Antoine, M., Reimers, K., Dickson, C., and Kiefer, P. (1997) J. Biol. Chem. 272, 29475-29481[Abstract/Free Full Text]
18. Kimura, H. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2165-2169[Abstract/Free Full Text]
19. Bajetto, A., Schettini, G., and Chimini, G. (1999) Brain Res. 818, 565-569[CrossRef][Medline] [Order article via Infotrieve]
20. Johnson, G. R., Saeki, T., Auersperg, N., Gordon, A. W., Shoyab, M., Salomon, D. S., and Stromberg, K. (1991) Biochem. Biophys. Res. Commun. 180, 481-488[CrossRef][Medline] [Order article via Infotrieve]
21. Johnson, G. R., Saeki, T., Gordon, A. W., Shoyab, M., Salomon, D. S., and Stromberg, K. (1992) J. Cell Biol. 118, 741-751[Abstract/Free Full Text]
22. Moroianu, J., and Riordan, J. F. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1677-1681[Abstract/Free Full Text]
23. Singh, D. P., Ohguro, N., Kikuchi, T., Sueno, T., Reddy, V. N., Yuge, K., Chylack, L. T., Jr., and Shinohara, T. (2000) Biochem. Biophys. Res. Commun. 267, 373-381[CrossRef][Medline] [Order article via Infotrieve]
24. Addison, C., Jenkins, J., and Sturzbecher, H. W. (1990) Oncogene 5, 423-426[Medline] [Order article via Infotrieve]
25. Mizushima, S., and Nagata, S. (1990) Nucleic Acids Res. 18, 5322-5323[Free Full Text]
26. Robbins, J., Dilworth, S. M., Laskey, R. A., and Dingwall, C. (1991) Cell 64, 615-623[CrossRef][Medline] [Order article via Infotrieve]
27. Zacksenhaus, E., Bremner, R., Phillips, R. A., and Gallie, B. L. (1993) Mol. Cell. Biol. 13, 4588-4599[Abstract/Free Full Text]
28. Makkerh, J. P. S., Dingwall, C., and Laskey, R. A. (1996) Curr. Biol. 6, 1025-1027[CrossRef][Medline] [Order article via Infotrieve]
29. Mosevitsky, M., Novitskaya, V. A., Iogannsen, M. G., and Zabezhinsky, M. A. (1989) Eur. J. Biochem. 185, 303-310[Medline] [Order article via Infotrieve]
30. Singh, D. P., Ohguro, N., Chylack, L. T., Jr., and Shinohara, T. (1999) Invest. Ophthalmol. Vis. Sci. 40, 1444-1451[Abstract/Free Full Text]
31. Lin, Y.-Z., Yao, S. Y., and Hawiger, J. (1996) J. Biol. Chem. 271, 5305-5308[Abstract/Free Full Text]
32. Klingenberg, O., Wiedlocha, A., Rapak, A., Munoz, R., Falnes, P., and Olsnes, S. (1998) J. Biol. Chem. 273, 11164-11172[Abstract/Free Full Text]
33. Mehta, V. B., Connors, l., Wang, H.-C. R., and Chiu, I.-M. (1998) J. Biol. Chem. 273, 4197-4205[Abstract/Free Full Text]
34. Bailly, K., Soulet, F., Leroy, D., Almaric, F., and Bouche, G. (2000) FASEB J. 14, 333-344[Abstract/Free Full Text]
35. Hawker, J. R., Jr., and Granger, H. J. (1992) Am. J. Physiol. 262, 1527-1537
36. Zhan, X., Hu, X., Friesel, R., and Maciag, T. (1993) J. Biol. Chem. 268, 9611-9620[Abstract/Free Full Text]
37. Prudovsky, I., Savion, N., Zhan, X., Friesel, R., Xu, J., Hou, J., McKeehan, W. L., and Maciag, T. (1994) J. Biol. Chem. 269, 31720-31724[Abstract/Free Full Text]
38. Wiedlocha, A., Falnes, P. O., Rapak, A., Munoz, R., Klingenberg, O., and Olsnes, S. (1996) Mol. Cell. Biol. 16, 270-280[Abstract]
39. Cao, Y., Ekstrom, M., and Pettersson, R. F. (1993) J. Cell Sci. 104, 77-87[Abstract]
40. Jouanneau, J., Gavrilovic, J., Caruelle, D., Jaye, M., Moens, G., Caruelle, J. P., and Thiery, J. P. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 2893-2897[Abstract/Free Full Text]
41. Ge, H., Si, Y., and Roeder, R. G. (1998) EMBO J. 17, 6723-6729[CrossRef][Medline] [Order article via Infotrieve]
42. Almaric, F., Bouche, G., Bonnet, H., Brethenou, P., Roman, A. M., Truchet, I., and Quarto, N. (1994) Biochem. Pharmacol. 47, 111-115[CrossRef][Medline] [Order article via Infotrieve]
43. March, C. J., Mosley, B., Larsen, A., Cerreti, D. P., Braedt, G., Price, V., Gillis, S., Henney, C. S, and Kronheim, S. R. (1985) Nature 315, 641-647[CrossRef][Medline] [Order article via Infotrieve]
44. Burgess, W. H., and Maciag, T. (1989) Ann. Rev. Biochem. 58, 575-606[CrossRef][Medline] [Order article via Infotrieve]
45. Ornits, D. M., and Itoh, N. (2001) Genome Biol. 2, 3005.1-3005.12
46. Munoz-Sanjuan, I., Smallwood, P. M., and Nathans, J. (2000) J. Biol. Chem. 275, 2589-2597[Abstract/Free Full Text]


Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Ann. Surg. Oncol.Home page
S. Yamamoto, Y. Tomita, Y. Hoshida, E. Morii, T. Yasuda, Y. Doki, K. Aozasa, H. Uyama, H. Nakamura, and M. Monden
Expression Level of Hepatoma-Derived Growth Factor Correlates with Tumor Recurrence of Esophageal Carcinoma
Ann. Surg. Oncol., July 1, 2007; 14(7): 2141 - 2149.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Uyama, Y. Tomita, H. Nakamura, S. Nakamori, B. Zhang, Y. Hoshida, H. Enomoto, Y. Okuda, M. Sakon, K. Aozasa, et al.
Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer.
Clin. Cancer Res., October 15, 2006; 12(20): 6043 - 6048.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
A. V. Tkatchenko, P. A. Walsh, T. V. Tkatchenko, S. Gustincich, and E. Raviola
Form deprivation modulates retinal neurogenesis in primate experimental myopia
PNAS, March 21, 2006; 103(12): 4681 - 4686.
[Abstract] [Full Text] [PDF]


Home page
Ann. Surg. Oncol.Home page
K. Yoshida, Y. Tomita, Y. Okuda, S. Yamamoto, H. Enomoto, H. Uyama, H. Ito, Y. Hoshida, K. Aozasa, H. Nagano, et al.
Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Hepatocellular Carcinoma
Ann. Surg. Oncol., February 1, 2006; 13(2): 159 - 167.
[Abstract] [Full Text] [PDF]